

Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

<https://marketpublishers.com/r/GA70D7B4D7FBEN.html>

Date: October 2021

Pages: 180

Price: US\$ 2,400.00 (Single User License)

ID: GA70D7B4D7FBEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:

Research Methodology

Global & Regional Market Analysis

Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion

Market & Drug Sales Insight 2020 Till 2026

Approved Drug In Market: 2 Drugs

Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026

Future Market Assessment By Indication Till 2026

Ongoing Clinical Trials Assessment by Status, Phase & Region

Key Market Dynamics

Competitor Landscape

The advancement in the field of biotechnology has promoted the recognition of the presence of targetable genomic alterations across multiple tumor types. Lately, researchers have identified NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 encoding the neurotrophin receptors TRKA, TRKB, and TRKC respectively as the oncogenic driver in several adult and pediatric cancers. Their critical role in the development, progression, and metastasis of cancer has made it potential target as an alternative for the treatment for the cancer. Since then, researchers have indulged in several research and development activities for the development of effective TRK inhibitors.

Currently, two TRK inhibitors including Vitrakvi and Rozlytrek have gained approval bodies for the management of NTRK positive solid tumors. The commercial launch of these drugs in the market has shown to completely transform the paradigm treatment of NTRK positive cancer. Since their introduction into the market, these drugs have shown high adoption rates which is mainly attributed to their high specificity and selectivity to NTRK genes, and its ability to overcome the limitation of conventional cancer therapies. Apart from this, these drugs have shown to cross the blood brain barrier, thus indicating its potential role in brain tumors.

In addition to approved drugs, the global pipeline of TRK inhibitors is highly crowded which suggests a brighter future of these inhibitors. The other TRK inhibitors in the pipeline are mainly developed to overcome the resistance to first generation TRK inhibitors. Selitrectinib (LOXO-195) and Repotrectinib (TPX-005) are the two next generation TRK inhibitors which have efficacy against TRK with acquired resistance. Currently, these are present in phase-II clinical trial and are expected to enter the market during the forthcoming years. Furthermore, several other potential candidates including Taletrectinib, VMD928, ICP723, and CHC2014 are also present in early phase of clinical trials and have shown promising preclinical activities.

The overall TRK inhibitor market is highly competitive and the key players working in market are AstraZeneca, Pfizer, Bayer, Loxo Oncology, Innocare, Ono Pharmaceutical, and Turning Point Therapeutics. The pharmaceutical giants have adopted several strategies to remain at forefront including agreement, mergers, joint ventures, collaboration, or acquisitions. For instance in May, 2021 AUM Biosciences entered into collaboration agreement with Handok and CMG Pharmaceutical for the worldwide development, manufacturing, and commercialization rights of CHC2014 which is highly specific and efficacious pan-TRK inhibitor.

Currently, the global TRK inhibitor market is present at nascent stage owing to the

approval of two drugs. However, it is expected that the coming years will witness tremendous growth rates in the market which is mainly due to increase in prevalence of cancer and the unmet need for the targeted therapy. Apart from this, the increase in awareness about the availability of drugs, upcoming new drugs approval, and rise in government initiatives will also boost the growth of market.

United States is anticipated to have a dominant share in the market during the forecast period, due to rise in awareness about new drugs for treatment, availability of all major companies in the region, the introduction of new drugs, and high prevalence of cancer in the region. Apart from this, the presence of favorable reimbursement policies including Vitrakvi Co-Pay by Bayer or Rozlytrek Co-Pay by Genentech to reduce the out of pocket cost associated with drugs will also increase the adoption rates of TRK inhibitor drugs in the region.

The report provides insights into the patent, price, dosage and sales analysis of the currently approved TRK inhibitors. On the basis of indication, the market is segment into lung, colorectal, breast, glioblastoma and papillary thyroid cancer. Keeping in mind the various driver and challenges, the future outlook of TRK inhibitors has also been analyzed in the report.

Contents

1. INTRODUCTION TO TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

1.1 Overview to TRK Inhibitors

1.2 Evolution of TRK Inhibitors

2. TRK - POTENTIAL TARGET IN CANCER THERAPY

3. TRK INHIBITORS MECHANISM OF ACTION

4. GLOBAL TRK INHIBITOR MARKET INSIGHT

4.1 Market Overview

4.2 Current Market Trends

5. TRK INHIBITORS MARKET REGIONAL ANALYSIS

5.1 US

5.2 Europe

5.3 Japan

5.4 Rest of World

6. TRK INHIBITORS MARKET BY INDICATION

6.1 Lung Cancer

6.2 Breast Cancer

6.3 Colorectal Cancer

6.4 Papillary Thyroid Cancer

6.5 Glioblastoma

7. VITRAKVI (LAROTRECTINIB) – FIRST APPROVED TRK INHIBITOR

7.1 Overview

7.2 Patents & Assignees

8. VITRAKVI (LAROTRECTINIB) – COMMERCIAL INFORMATION

8.1 Pricing

8.2 Sales Analysis

9. ROZLYTREK (ENTRECTINIB) – SECOND APPROVED TRK INHIBITOR

9.1 Overview

9.2 Patents & Assignees

10. ROZLYTREK (ENTRECTINIB) – COMMERCIAL INFORMATION

10.1 Price & Dosage Analysis

10.2 Sales Analysis

11. TRK INHIBITORS SALES FORECAST 2026

11.1 Vitrakvi Sales Forecast

11.2 Rozlytrek Sales Forecast

12. KEY TRK INHIBITORS DRUGS IN CLINICAL DEVELOPMENT

12.1 Selitrectinib

12.2 Repotrectinib

12.3 Taletrectinib

12.4 VMD928

12.5 ICP723

12.6 CHC2014

13. GLOBAL TRK INHIBITORS CLINICAL PIPELINE (BY DRUGS) INSIGHT

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-III

14. MARKETED TRK INHIBITORS CLINICAL INSIGHT

15. GLOBAL TRK INHIBITORS CLINICAL PIPELINE (BY TRIALS/STUDIES) INSIGHT

15.1 By Phase

15.2 By Status

15.3 By Region

16. GLOBAL TRK INHIBITORS MARKET FUTURE OUTLOOK

17. GLOBAL TRK INHIBITOR MARKET DYNAMICS

17.1 Market Drivers

17.2 Market Challenges

18. COMPETITIVE LANDSCAPE

18.1 AstraZeneca

18.2 Aum Biosciences

18.3 Bayer

18.4 CMG Pharmaceutical

18.5 Eli Lilly & Company

18.6 InnoCare

18.7 Loxo Oncology

18.8 Ono Pharmaceutical

18.9 Pfizer

18.10 Roche

18.11 Turning Point Therapeutics

List Of Figures

LIST OF FIGURES

- Figure 1-1: Resistance Mechanism in First Generation TRK Inhibitors
- Figure 1-2: Development Timeline of TRK Inhibitors
- Figure 2-1: Neurotrophins & Their Receptors
- Figure 2-2: Role of TRK Signaling in Cancer
- Figure 3-1: TRK Inhibitors – Mechanism of Action
- Figure 4-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 4-2: Global – TRK Inhibitors Market by Product (US\$ Million), 2020
- Figure 4-3: Global – TRK Inhibitors Market by Product (%), 2020
- Figure 4-4: Global – TRK Inhibitors Market by Product (US\$ Million), Q1, 2021
- Figure 4-5: Global – TRK Inhibitors Market by Product (US\$ Million), Q2, 2021
- Figure 4-6: Global – TRK Inhibitors Market by Product (US\$ Million), H1, 2021
- Figure 4-7: Global – TRK Inhibitors Market by Product (%), H1, 2021
- Figure 4-8: Global – TRK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 4-9: TRK Inhibitor - Market by Region (US\$ Million), 2020
- Figure 4-10: TRK Inhibitors Market by Region (%), 2020
- Figure 5-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 5-2: TRK Inhibitor Market – US vs. ROW (US\$ Million), 2020
- Figure 5-3: TRK Inhibitor Market – US vs. ROW (%), 2020
- Figure 5-4: US - TRK Inhibitors Market by Product (US\$ Million), 2020
- Figure 5-5: US - TRK Inhibitors Market by Product (%), 2020
- Figure 5-6: US - TRK Inhibitors Market by Product (US\$ Million), H1, 2021
- Figure 5-7: US - TRK Inhibitors Market by Product (%), H1, 2021
- Figure 5-8: US – TRK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 5-9: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 5-10: Europe – Cancer Incidences by Country (Million), 2020
- Figure 5-11: TRK Inhibitor Market – Europe vs. ROW (US\$ Million), 2020
- Figure 5-12: TRK Inhibitor Market – Europe vs. ROW (%), 2020
- Figure 5-13: Europe - TRK Inhibitors Market by Product (US\$ Million), 2020
- Figure 5-14: Europe - TRK Inhibitors Market by Product (%), 2020
- Figure 5-15: Europe - TRK Inhibitors Market by Product (US\$ Million), H1, 2021
- Figure 5-16: Europe - TRK Inhibitors Market by Product (%), H1, 2021
- Figure 5-17: Europe – TRK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 5-18: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 5-19: TRK Inhibitors Market – Japan vs. ROW (US\$ Million), 2020
- Figure 5-20: TRK Inhibitors Market – Japan vs. ROW (%), 2020

- Figure 5-21: Japan - TRK Inhibitors Market by Product (US\$ Million), 2020
- Figure 5-22: Japan - TRK Inhibitors Market by Product (%), 2020
- Figure 5-23: Japan - TRK Inhibitors Market by Product (US\$ Million), H1, 2021
- Figure 5-24: Japan - TRK Inhibitors Market by Product (%), H1, 2021
- Figure 5-25: Japan – TRK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 5-26: China – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 5-27: South Korea – Cancer Incidences & Deaths, 2020 & 2025
- Figure 5-28: TRK Inhibitors Market – China vs. ROW (%), 2020
- Figure 5-29: ROW - TRK Inhibitors Market by Product (US\$ Million), H1, 2021
- Figure 5-30: ROW - TRK Inhibitors Market by Product (%), H1, 2021
- Figure 5-31: ROW – TRK Inhibitors Market Size (US\$ Million), 2020 - 2026
- Figure 6-1: Global – Lung Cancer Incidences, 2020 - 2026
- Figure 6-2: Global – Non-Small Cell Lung Cancer Incidences, 2020 - 2026
- Figure 6-3: Global – NTRK Positive Lung Cancer Incidences, 2020 - 2026
- Figure 6-4: Global – NTRK Positive Non-Small Cell Lung Cancer Incidences, 2020 - 2026
- Figure 6-5: Global – Breast Cancer Incidences, 2020 - 2026
- Figure 6-6: Global – NTRK Positive Breast Cancer Incidences, 2020 - 2026
- Figure 6-7: Global – Colorectal Cancer Incidences, 2020 - 2026
- Figure 6-8: Global – NTRK Positive Colorectal Cancer Incidences, 2020 - 2026
- Figure 6-9: Global – Thyroid Cancer Incidences, 2020 - 2026
- Figure 6-10: Global – Papillary Thyroid Cancer Incidences, 2020 - 2026
- Figure 6-11: Global – NTRK Positive Papillary Thyroid Cancer Incidences, 2020 - 2026
- Figure 6-12: Global – Brain Cancer Incidences, 2020 - 2026
- Figure 6-13: Global – Gliomlastoma Incidences, 2020 - 2026
- Figure 6-14: Global – NTRK Positive Gliolastoma Incidences, 2020 - 2026
- Figure 7-1: US – Vitrakvi Orphan Status & FDA Approval Year
- Figure 7-2: Vitrakvi – Approval Year by Region
- Figure 7-3: US – Vitrakvi Patent Approval & Expiration Year
- Figure 7-4: US – Vitrakvi Patents by Assignees
- Figure 8-1: US – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (US\$), October'2021
- Figure 8-2: US – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg Capsules (US\$), October'2021
- Figure 8-3: US – Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (US\$), October'2021
- Figure 8-4: UK – Cost of Supply of 56 Capsules & Per Unit Cost of Virtakvi 25mg Capsules (Euro/US\$), October'2021
- Figure 8-5: UK – Cost of Supply of 60 Capsules & Per Unit Cost of Virtakvi 100mg

Capsules (Euro/US\$), October'2021

Figure 8-6: UK – Cost of Supply of 100ml & Per Unit Cost of Virtakvi 20mg/ml Oral Solution (Euro/US\$), October'2021

Figure 8-7: Virtakvi – Recommended Initial & Dose Reductions in Adult/Pediatric Patients with at Least 1.0 Meter-Squared (mg)

Figure 8-8: Virtakvi – Recommended Initial & Dose Reductions in Pediatric Patients with Less than 1.0 Meter-Squared (mg/m²)

Figure 9-1: US – Rozlytrek Orphan Drug Designations Approval by Indication

Figure 9-2: Japan – Rozlytrek Approval Year by Indication

Figure 9-3: Rozlytrek – Approval Year by Region

Figure 9-4: US – Rozlytrek Patent Approval & Expiration Year

Figure 10-1: US – Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (US\$), October'2021

Figure 10-2: US – Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (US\$), October'2021

Figure 10-3: UK – Cost of Supply of 30 Capsules & Per Unit Cost of Rozlytrek 100mg Capsules (Euro/US\$), October'2021

Figure 10-4: UK – Cost of Supply of 90 Capsules & Per Unit Cost of Rozlytrek 200mg Capsules (Euro/US\$), October'2021

Figure 10-5: Rozlytrek – Recommended Initial & Dose Reductions in Adult/Pediatric Patients with BSA Greater than 1.50 m² (mg/day)

Figure 10-6: Rozlytrek – Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 1.11 to 1.50 m² (mg/day)

Figure 10-7: Rozlytrek – Recommended Initial & Dose Reductions in Pediatric Patients with BSA of 0.91 to 1.1 m² (mg/day)

Figure 10-8: Global - Rozlytrek Annual Sales (CHF/US\$ Million), 2019 & 2020

Figure 10-9: US - Rozlytrek Annual Sales (CHF/US\$ Million), 2019 & 2020

Figure 10-10: Rozlytrek - Annual Sales by Region (CHF/US\$ Million), 2020

Figure 10-11: Rozlytrek - Annual Sales by Region (%), 2020

Figure 10-12: Global - Rozlytrek Quarterly Sales (CHF/US\$ Million), 2020

Figure 10-13: Global - Rozlytrek Quarterly Sales (CHF/US\$ Million), Q1 & Q2'2021

Figure 10-14: Rozlytrek – Sales by Region (CHF/US\$ Million), Q1'2021

Figure 10-15: Rozlytrek – Sales by Region (CHF/US\$ Million), Q2'2021

Figure 10-16: Rozlytrek – Half Year Sales by Region (CHF/US\$ Million), H1'2021

Figure 10-17: Rozlytrek – Half Year Sales by Region (%), H1'2021

Figure 11-1: Global – Vitrakvi Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-2: Global – Rozlytrek Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-3: US – Rozlytrek Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-4: Europe – Rozlytrek Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-5: Japan – Rozlytrek Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-6: ROW – Rozlytrek Sales Forecast (US\$ Million), 2021 - 2026

Figure 12-1: Selitrectinib – Phase-I/II Clinical Study Initiation & Primary Completion Year

Figure 12-2: Taletrectinib – Phase-II Clinical Study Initiation & Primary Completion Year

Figure 12-3: VMD928 – Phase-I Clinical Study Initiation & Primary Completion Year

Figure 12-4: ICP723 – Phase-I/II Clinical Study Initiation & Primary Completion Year

Figure 13-1: Global TRK Inhibitors Clinical Pipeline insight (Number of drugs), 2021 till 2026

Figure 15-1: Global – TRK Inhibitor Clinical Trials Insight by Phase (Number of Trials), October'2021

Figure 15-2: Global - TRK Inhibitor Clinical Trials Insight by Phase (%),October'2021

Figure 15-3: Global - TRK Inhibitor Clinical Trials Insight by Status (Number of Trials), October'2021

Figure 15-4: Global - TRK Inhibitor Clinical Trials Insight by Status (%),October'2021

Figure 15-5: TRK Inhibitor – Clinical Trials Insight by Region (Number of Trials), October'2021

Figure 15-6: North America – Clinical Trial by Countries, October'2021

Figure 15-7: TRK Inhibitor – Clinical Trials Insight by Region, October'2021

Figure 15-8: North America – Clinical Trial by Countries (%),October'2021

Figure 17-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2040

Figure 17-2: Global – TRK Inhibition Market Drivers

Figure 17-3: Global – TRK Inhibitor Market Challenges

I would like to order

Product name: Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

Product link: <https://marketpublishers.com/r/GA70D7B4D7FBEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA70D7B4D7FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970